BUSINESS

Latuda Succeeds in PIII Schizophrenia Study, Japan NDA Submission Planned by September

January 11, 2019
Sumitomo Dainippon Pharma said on January 10 that its atypical antipsychotic Latuda (lurasidone) hit the primary endpoint in a global PIII study enrolling patients with schizophrenia, with the company now planning to file the drug in Japan by the end…

To read the full story

BUSINESS

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…